Enliven Therapeutics (ELVN) stock
ELVN's Quality Score fell 3 points on Tue, Oct 6, to -1. Its average daily range rose to 5.1%, with a $106M loss over four quarters and no positive free cash flow. 2 more reasons, for Pro members.
Follow ELVN's trial news. Pro members can get an alert when Enliven Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
27.0% more shares than a year ago.
5 more reasons behind ELVN's -1, for Pro members
What's next for ELVN, and how long its cash lasts
From Enliven Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2030 (8-K, Aug 5).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Aug 13, 2025)
- At-the-market share sales program (S-3ASR, filed Aug 13, 2025)
Insiders
Director Garland J. Scott sold 13,000 shares on Oct 1. 25 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why ELVN scores -1
PoorTrending up, 1 of 14 checks firingWhat the Quality Score means
- +2Run-up 116% over 12 months
- −2Dilution 27.0% more shares outstanding than a year ago
- Chart checks adds
- Long-term trend adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Expected to report Wed Nov 11, after the close
After its last 4 reports it closed +1.6% on average, higher 3 of 4 times.
What would turn ELVN's score around: 7 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ELVN has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1424.6
- MACD (12, 26, 9)Below signal
- 50-day average$54.75
- 200-day average$40.69
- ADX 1444.9
- Support$38.58
- Resistance$43.05
- Bollinger Bands (20, 2)Inside
- Volume1.6x
How ELVN ranks in Biotech
ELVN is #154 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
EIKNOpen for its score
ELDNOpen for its score
ENTXOpen for its score
EPRXOpen for its score
ELVN1/14-1
When does ELVN report earnings, and what happens after?
Expected to report Wed Nov 11, after the close (in 36 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 5, 2026After close | After close | -0.6% | +0.9% | -3.0% |
| May 7, 2026After close | After close | +3.1% | +1.1% | +6.9% |
| Mar 3, 2026After close | After close | -0.6% | +4.3% | +5.2% |
| Nov 12, 2025After close | After close | +0.1% | -0.1% | +8.9% |
Who is trading ELVN
ELVN insider trades
2 insiders sold $52.3M across 7 filings in the last 6 months. No open-market buys on record. The newest:
ELVN's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About Enliven Therapeutics
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of ELVN's score, with the points and the reason
- All 14 checks on ELVN and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ELVN
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.